|Table of Contents|
Role of adiponectin in acute biliary pancreatitis – a prospective case–control study
The prevalence of acute pancreatitis (AP) is increasing and is paralleled by an increased prevalence of obesity. High levels of adipocytokines, including adiponectin, can indicate a large amount of visceral fat surrounding the pancreas. Our aim is to study the ability of serum adiponectin to predict the clinical severity of acute biliary pancreatitis and its potential use as a marker of body mass index (BMI). Data were collected from 102 patients in this prospective study who were diagnosed with initial acute biliary pancreatitis between January 2010 and April 2013. Waist circumference and BMI were measured and serum adiponectin levels were analysed at the time of admission using enzyme-linked immunosorbent assay (ELISA). In addition, plasma samples of adiponectin were taken from an age-, sex- and BMI-matched control group. Our results showed that BMI was significantly correlated with pancreatitis severity (P=0.007) and there was a negative relationship between BMI and adiponectin levels with a Pearson correlation coefficient of <0.45 (P=0.001). Serum adiponectin did not correlate with weight or waist circumference and, furthermore, serum adiponectin was significantly lower in patients with AP than in the control subjects (P<0.0001). Obesity is a risk factor for developing severe AP and we demonstrate that measuring the serum adiponectin level can be used as a new marker for BMI at the time of hospital admission; however, adiponectin failed to serve as predictive marker of clinical severity.